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Abstract
Background: The aims of this study were to evaluate the microbio-
logical data for effective infection control and specific antimicrobial 
stewardship, and to report the epidemiology of intensive care unit 
(ICU)-acquired infections and the local antimicrobial resistance of 
pathogens 
Methods: Data were collected between January 2011 and October 
2016 from the cardiology and cardiovascular surgery patients. The 
identification and antimicrobial susceptibility analyses of clinical patho-
genic isolates were determined by the automatic device system. 
Results: Klebsiella pneumoniae was detected increasingly and signifi-
cantly (p=0.048) resistant to imipenem (IMP). Acinetobacter baumanii 
was found increasingly and significantly (p=0.045, p=0.030, p=0.006, 
p=0.027) resistant to amikacin (AN), gentamicin (GN), trimethoprim-
sulfamethoxazole (SXT) and tetracycline (TE), respectively. There was 
a significantly decrease in the resistant rates of IMP, piperacillin-tazo-
bactam (TPZ), meropenem (MEM) and ciprofloxacin (CIP) for Pseudo-
monas spp. (p=0.048). All gram-negative bacteria isolates showed 
significantly increasing resistance rates to cefepime (CEP) (p=0.015). 
Also, all gram-positive bacteria demonstrated significantly decreasing 
resistance rates to teicoplanin (TEC) (p=0.034). 
Conclusion: This study suggets that inadequacy of infection control 
measures such as hand hygiene and patient isolation may have con-
tributed to increasing the rates of carbapenem-resistant K. pnemoniae 
(CR-KP) isolates in recent years. 
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Introduction
The antimicrobial stewardship in intensive care unit 
(ICU) is highly important  measurement to control 
antimicrobial resistance in most hospital. There are 
two main problems to this issue. Inappropriate usa-
ge of antibiotic therapy and poor concordance to 
the infection control policy. Both can lead to the 
occurrence of resistant pathogens by various mole-
cular mechanisms such as mutation, gene transfer 
and selection of the resistant strains [1, 2]. Recently, 
most ICU-acquired infection are due to pathogens 
like methicillin-resistant Staphylococci, multidrug-re-
sistant Pseudomonas aeruginosa and Acinetobacter 
species. Additionaly, carbapenem resistant K. pneu-
moniae (CR-KP) are detected more frequently in the 
recent years worldwide [3-5]. Therefore, awareness 
about the current local epidemiology and antimicro-
bial susceptibility of bacterial isolates is an important 
factor in prescribing true empiric antibiothreapy in 
ICU [6, 7]. Despite this fact, medical treatment op-
tions of multidrug-resistant pathogens are limited 
[8]. 
The aim of this study is to report the epidemio-
logy of ICU-acquired infections and the local anti-
microbial resistance of microorganism isolates over 
a 6- year period.
Materials and Methods
Patients
Data were collected between January 2011-October 
2016, retrospectively, from admitted adult cardio-
logy and cardiovascular surgery (CVS) patients at 
Bursa Yuksek Ihtisas Training and Research Hospi-
tal, Turkey. This hospital is a tertiary care hospital 
serving a 3-million population region. ICU-acquired 
infections were diagnosed after 48 hours of ICU 
admission according to Centers for Disease Control 
and Prevention guidelines [9]. Piperacillin-tazobac-
tam, imipenem, meropenem antibiotics were fre-
quently used in treatment of ICU-acquired infection 
caused by gram-negative bacteria and vancomycin, 
linezolid, daptomycin antibiotics were frequently 
used in treatment of ICU-acquired infection caused 
by gram-positive bacteria.
Microbiological analyses
Blood, urine, wound, sputum, tracheal aspirate and 
other clinical samples were collected from the pa-
tients who were prediagnosed with ICU-acquired 
infections. Cultivation of specimens were made and 
microbiological tests were used for identification of 
isolates. Bacterial isolates from blood cultures were 
detected using BACTEC 9240 (Becton Dickinson, 
USA). Identification and antimicrobial susceptibility 
analyses of pathogens were determined by the au-
tomatic device system (MicroScan Walkaway, Bec-
kman Coulter, USA). The following antibiotics were 
used for gram-negative microorganisms; amika-
cin (AN), amoxicillin-clavulanate (AMC), gentami-
cin (GN), imipenem (IMP), piperacillin-tazobactam 
(TPZ), cefepime (CEP), cefotaxime (CTX), trimetho-
prim-sulfamethoxazole (SXT), meropenem (MEM), 
ciprofloxacin (CIP), ceftazidime (CAZ), levofloxacin 
(LEV), tetracycline (TE), cefazolin (CZ) antimicrobial 
resistance ratios were established. For gram-positive 
microorganisms; ampicillin (AM), ciprofloxacin (CIP), 
teicoplanin (TEC), tetracycline (TE), trimethoprim-
sulfamethoxazole (SXT), vancomycin (VA), genta-
micin (GN). All antimicrobial resistance ratios were 
determined according to the minimal inhibitor con-
centration (MIC) values of the current EUCAST cri-
teria. Methicillin resistant Staphylococcus species 
was assessed according to cefoxitin MIC values. 
Candida species was differentiated by APIc AUX kit 
(bioMe r´ieux, France).  
Statistical analyses
Data were analyzed by SPSS program version 21.0 
with Fisher’s exact chi-square test and Pearson chi-
square test. Differences were accepted statistically 
significant at p<0.05.
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Results
The distribution of recovered pathogens in ICUs 
over a 6-year period is demonstrated in Table 1. Aci-
netobacter baumanii and coagulase-negative Sta-
phylococcus (CNS) were the most common patho-
gens recovered. The distribution of resistance rates 
of recoverd pathogens through three-year periods 
was determined. Antibiotic resistance rates of mi-
croorganisms between 2011-2012-2013 and 2014-
2015-2016 were combined and the total resistance 
rates in both periods were compared. A comparison 
between resistance rates in gram-negative patho-
gens during a 6-year period is demonstrated in Ta-
ble 2, 3. A second comparison between resistance 
rates in gram-positive bacteria over a 6-year period 
is shown in Table 4.
Table 1. Distribution of ICU-acquired pathogens over the 6-year period (2011-2016).
Microorganism isolates
2011 2012 2013 2014 2015 2016
No. % No. % No. % No. % No. % No. %
Acinetobacter baumannii 23 23.7 8 10 18 18.75 18 20.93  0 9 16.36
Acinetobacter spp. 2 2.1 10 12.5 7 7.29 10 11.62 16 21.33 6 10.90
Candida albicans  0 2 2.5 3 3.12 4 4.65  0  0
Candida spp. 6 6.2 2 2.5 5 5.20 3 3.48 1 1.33  0
Citrobacter spp. 1 1  0 2 2.08  0 1 1.33 2 3.63
Enterococcus spp.  0 4 5 3 3.12 2 2.32  0 2 3.63
Enterobacter spp. 1 1 2 2.5  0  0 1 1.33  0
Enterobacter aerogenes 1 1 1 1.25 1 1.04 5 5.81  0  0
Enterobacter cloacae  0 4 5 1 1.04 2 2.32  0 1 1.81
Enterococcus faecalis 5 5.2 2 2.5 8 8.33 4 4.65 3 4 4 7.27
Enterococcus faecium 3 3.1  0 3 3.12 1 1.16 1 1.33 1 1.81
Escherichia coli 11 11.3 5 6.25 6 6.25 3 3.48 10 13.33 5 9.09
Coagulase-negative staphylococci 8 8. 3 17 21.25 18 18.75 9 10.46 12 16 9 16.36
Klebsiella oxytoca  0 1 1.25  0  0  0  0
Klebsiella pneumoniae 8 8.2 3 3.75 2 2.08 8 9.30 3 4 5 9.09
Klebsiella spp.  0 3 3.75  0 2 2.32 6 8  0
Morganella morganii  0  0  0  0 1 1.33 1 1.81
Pseudomonas aeruginosa 2 2.1 3 3.75 10 10.41 4 4.65 3 4 3 5.45
Pseudomonas spp.  0  0 2 2.08 3 3.48 2 2.66  0
Proteus mirabilis  0  0 1 1.04 1 1.16  0  0
Providencia spp. 1 1.  0  0  0  0  0
Serratia marcescens 6 6.2  0 2 2.08  0 1 1.33 1 1.81
Staphylococcus aureus 16 16.5 13 16.25 1 1.04 7 8.13 13 17.33 6 10.90
Streptococcus pneumoniae 1 1  0 1 1.04  0 1 1.33  0
Stenotrophomonas maltophilia 1 1  0 2 2.08  0  0  0
Streptococcus spp. 1 1  0  0  0  0  0
Total 97 100 80 100 96 100 86 100 75 100 55 100
The InTernaTIonal arabIc Journal of anTImIcrobIal agenTs 
ISSN: 2174-9094
2017
Vol. 7 No. 2:4
doi: 10.3823/0809
This article is available at: www.intarchmed.com and www.medbrary.com 4
Table 2. Comparison of the antimicrobial resistance rates in different gram negative pathogens over two periods (2011-2013 versus 2014-2016).
Microorganism Period 
Amikacin Amoxicillin/Clavulanate Gentamicin Imipenem Piperacillin/Tazobactam Cefepime Cefotaxime
% P* % p % p % p % p % p % p
Enterobacter cloacae 2011-2013 0.0 100.0 0.0 0.0 20.0
1.00
0.0
0.143
25.0
1.00
2014-2016 0.0 100.0 0.0 0.0 0.0 66.7 33.3
E. coli 2011-2013 9.1
0.642
93.3
0.314
47.6
0.180
0.0
0.450
37.5
1.00
2014-2016 16.7 66.7 22.2 5.6 40.0
Klebsiella pneumoniae 2011-2013 7.7
0.343
50.0
1.00
69.2
1.00
0.0
0.048 
50.0
1.00
62.5
1.00
2014-2016 25.0 50.0 62.5 31.2 50.0 50.0
Klebsiella spp. 2011-2013 66.7
0.545
0.0 100.0
2014-2016 37.5 0.0 100.0
Serratia marcescens 2011-2013 0.0 100.0 0.0 0.0 0.0 12.5
1.00
2014-2016 0.0 100.0 0.0 0.0 0.0 0.0
Pseudomonas aeruginosa 2011-2013 7.1
1.00
7.1
0.521
33.3
0.262
0.0
2014-2016 14.3 28.6 0.0 0.0
Acinetobacter baumanii 2011-2013 83.0
0.045 
67.6 0.030 97.8
1.00
100.0
2014-2016 100.0 92.6 96.3 100.0
Acinetobacter spp. 2011-2013 33.3
0.184
78.9
0.222
76.5
0.721
94.7
1.00
94.7
1.00
2014-2016 59.1 59.4 81.2 100.0 100.0
Enterobacter aerogenes 2011-2013 0.0 100.0 0.0
0.464
0.0 0.0 0.0
0.196
0.0
2014-2016 0.0 100.0 40.0 0.0 0.0 60.0 0.0
Citrobacter spp. 2011-2013 33.3
1.00
33.3
1.00
33.3
1.00
2014-2016 0.0 33.3 0.0
Pseudomonas spp. 2011-2013 100.0
0.048 
100.0
0.048 
2014-2016 0.0 0.0
Proteus mirabilis 2011-2013 0.0
1.00
0.0 0.0 1.00
2014-2016 100.0 0.0 100.0
Gram Negative 
Microorganisms
2011-2013 37.5
0.190
92.9
0.057
50.0
0.620
47.1
0.902
36.0
0.569
53.8
0.015 
75.4
1.00
2014-2016 46.2 73.9 53.2 46.0 25.7 84.6 76.5
*: p<0.05
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Table 3. Comparison of antimicrobial resistance rates in different gram negative pathogens over two periods (2011-2013 versus 2014-2016).
Microorganism Period 
Trimethoprim/Sulfamethoxazole Meropenem Ciprofloxacin Ceftazidim Levofloxacin Tetracycline Cefazolin
% P* % p % p % p % p % p % p
Enterobacter cloacae 2011-2013 20.0
1.00
2014-2016 0.0
E. coli 2011-2013 76.5
1.00
0.0
0.450
2014-2016 80.0 5.6
Klebsiella pneumoniae 2011-2013 61.5
0.714
0.0
0.096
61.5
0.673
2014-2016 68.8 30.8 50.0
Klebsiella spp. 2011-2013 33.3
0.491
66.7
1.00
2014-2016 75.0 62.5
Serratia marcescens 2011-2013 0.0 0.0
0.22 
2014-2016 0.0 50.0
Pseudomonas aeruginosa 2011-2013 33.3
0.345
20.0
1.00
46.7
0.68
0.0
1.00
2014-2016 10.0 25.0 60.0 16.7
Acinetobacter baumanii 2011-2013 75.5
 0.06 
98.0
1.00
95.9
0.536
95.7
0.530
100.0 76.6
0.027 
2014-2016 100.0 100.0 100.0 100.0 100.0 100.0
Acinetobacter spp. 2011-2013 83.3
0.289
100.0 100.0 100.0
2014-2016 96.2 100.0 100.0 100.0
Enterobacter aerogenes 2011-2013 0.0
0.196
0.0 0.0 100.0
2014-2016 60.0 0.0 0.0 100.0
Citrobacter spp. 2011-2013 33.3
1.00
0.0
2014-2016 100.0 0.0
Pseudomonas spp. 2011-2013 100.0
0.048 
100.0
0.048 
2014-2016 0.0 0.0
Proteus mirabilis 2011-2013 0.0
2014-2016 0.0
Gram Negative 
Microorganisms
2011-2013 64.3
0.123
52.2
0.791
75.5
0.386
76.3
0.11 
88.1
0.757
78.0
0.055
100.0
0.381
2014-2016 76.5 50.0 81.2 86.7 85.3 100.0 87.5
*: p<0.05
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Table 4. Comparison of antimicrobial susceptibility rates in different gram positive pathogens over two periods (2011-2013 versus 2014-2016).
Microorganism Period 
Ampicillin Ciprofloxacin Teicoplanin Tetracycline Trimethoprim/Sulfamethoxazole Vancomycin Gentamicin
% P* % p % p % p % p % p % p
Staphylococcus aureus 2011-2013 100.0
0.248
75.0
0.111
0.0 53.3
0.693
33.3
0.290
0.0
2014-2016 81.2 38.5 0.0 42.9 15.4 0.0
Enterococcus faecalis 2011-2013 0.0
0.169
25.0
0.315
10.0
0.476
70.0
0.659
0.0
2014-2016 18.2 62.5 0.0 54.5 0.0
Enterococcus spp. 2011-2013 50.0
1.00
100.0 0.0
2014-2016 50.0 100.0 0.0
CNS** 2011-2013 100.0
0.492
7.1
0.261
23.3
0.547
48.8
1.00
0.0 46.3
0.474
2014-2016 93.1 0.0 33.3 52.4 0.0 56.7
Enterococcus faecium 2011-2013 100.0 33.0
0.500
33.0
0.500
2014-2016 100.0 0.0 0.0
Gram positive 
microorganisms
2011-2013 32.0
0.747
55.0
0.758
6.8
0.034 
42.5
1.00
42.5
0.833
1.9
0.524
46.3
0.474
2014-2016 37.5 47.6 0.0 43.9 38.2 0.0 56.7
*: P<0.05; **: Coagulase-negative Staphylococcus.
Discussion
Hospitalization in ICU is an important risk factor 
to acquire infection with carbapenem resistant K. 
pneumoniae (CR-KP), because of usage of many 
invasive devices such as urinary catheters, central 
venous catheters, mechanical ventilation and the 
possibility of transmission infection between pa-
tients. Additionaly, broad-spectrum antimicrobial 
drugs such as carbapenems are frequently used 
in ICUs and these drugs are known to contribu-
te for emergence of CR-KP [10-12]. In our study, 
K. pneumoniae was detected increasingly and 
significantly resistant to imipenem, because our 
tertiary care hospital admitted cardiology and 
cardiovascular surgery patients (CVS) from refe-
rral hospitals to our ICUs. We suspect that these 
patients have contributed for spread of CR-KP in 
our ICUs. In addition, the insufficient isolation of 
infected patients and inadequate ventilation in our 
ICUs have increased rates of infection and isola-
tion of resistant pathogens among patients du-
ring the two compared periods (2014-2016 versus 
2011-2013) as shown in Table 2-4. Also, similar 
increasing rates were observed in relation to use 
of urinary catheterization and the length period 
of usage it. Both these two factors were most 
probably increased infection with CR-KP in our 
intensive care units. 
In our study, multidrug-resistant A. baumanii 
isolates were the most common cause of infec-
tions among our patients in ICUs as it has been 
recoded worldwide [13-16]. The increase in anti-
biotic resistance rates among A. baumanii isolates 
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was significant (Table 2-3). It has been reported that 
carbapenem-resistant Acinetobacter isolates can be 
increased rapidly and become a significant problem 
in intensive care unit patients. Additionaly, rates of 
resistant Acinetobacter strains are observed to be 
higher in countries where carbapenems are inten-
sely used [17, 18]. 
Studies have also shown an increasing carba-
penem-resistance in P. aeruginosa isolates from 
ICU-acquired infections [19-21]. In our study, there 
was a significantly decrease in the resistant rates of 
Pseudomonas spp. and P. aeruginosa to IMP, TPZ, 
MEM and CIP, but both were not istatistically signi-
ficant. In addition, decreased rates of resistance to 
IMP and MEM were detected in all gram-negative 
pathogens and these were not statistically signifi-
cant (Table 2-3). The reason for this decrease may 
be due the fact that in our hospital, our physici-
ans used less empirical treatment in ICU-acquired 
infections and they are preferring to apply mostly 
treatment based on culture results. This approach 
may has led to reduce the occcurrence of carbape-
nem-resistant pathogens in our hospital. It is also 
impotant to note that our hospital's microbiology 
laboratory provided 24-hour service, and offer a 
rapid assessment of positive blood cultures and the 
result of gram-staining. 
In our hospital, physcians are prefering treatment 
of gram-positive bacterial infections with van-
comycin, daptomycin and linezolid instead of teico-
planin. Despite this treatment approch, there was 
overall no change in rates of resistant among all 
gram-positive bacteria to these 3 drugs, but there 
was statistically significant decreased in resistant to 
TEC (Table 4). However, various studies have shown 
that teicoplanin could theoretically represent an ac-
ceptable alternative drug, since it has comparable 
efficacy compared to vancomycin in various disease 
conditions and excellant bone diffusion [22]. Exten-
sive use of teicoplanin in ICU patienst may result in 
development of increased resistance rates in gram-
posive bacteria, whereas the usage of vancomycin 
occasionally during empirical therapy, and according 
to MIC values were the main reasons for not incre-
asing vancomycin resistance rates in gram-positive 
bacteria in this study [23-26]. 
In conclusion, this study showes that close coope-
ration between microbiology laboratory and phys-
cians has been associated with decrease in carbape-
nem and vancomycin resistance rates in pathogens 
recovered from ICU's patients. 
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